Sökning: onr:"swepub:oai:gup.ub.gu.se/49951" >
A prospective, rand...
A prospective, randomized, multi-centre trial of systemic adjuvant chemotherapy versus no additional treatment in liver transplantation for hepatocellular carcinoma
-
- Söderdahl, G. (författare)
- Karolinska Institutet
-
Bäckman, Lars (författare)
-
Isoniemi, H. (författare)
-
visa fler...
-
- Cahlin, Christian, 1959 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
Hockerstedt, K. (författare)
-
Broome, U. (författare)
-
Makisalo, H. (författare)
-
- Friman, Styrbjörn, 1948 (författare)
- Gothenburg University,Göteborgs universitet,Institutionen för kliniska vetenskaper,Institute of Clinical Sciences
-
- Ericzon, B. G. (författare)
- Karolinska Institutet
-
visa färre...
-
(creator_code:org_t)
- Frontiers Media SA, 2006
- 2006
- Engelska.
-
Ingår i: Transplant international. - : Frontiers Media SA. - 0934-0874. ; 19:4, s. 288-94
- Relaterad länk:
-
https://gup.ub.gu.se...
-
visa fler...
-
http://kipublication...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- The role of adjuvant systemic chemotherapy in liver transplantation (LT) for hepatocellular carcinoma (HCC) is controversial. Here, we report the results of a Nordic prospective, randomized, multi-centre trial of systemic low-dose doxorubicin in patients with HCC. Between February 1996 and April 2004, 46 patients were randomized to receive either neoadjuvant doxorubicin in combination with LT (chemo group; n = 19) or LT alone (control group; n = 27). In the chemo group, doxorubicin was administered intravenously, 10 mg/m(2) weekly, starting from acceptance onto the waiting list for LT. One intraoperative dose of 15 mg/m(2) was given, and postoperatively doxorubicin was given weekly at a dose of 10 mg/m(2), depending on the clinical course, up to a cumulative dose of 400 mg/m(2). Actuarial, 3-year overall survival (OS) and disease-free survival (DFS) in the control group were 70% and 50%, respectively. In the chemo group, both OS and DFS were 63%. Freedom from recurrence at 3 years was 55% in the control group and 74% in the chemo group. None of the differences was statistically significant. Neoadjuvant treatment with systemic low-dose doxorubicin seems not to improve either survival or freedom from recurrence in patients with HCC undergoing LT.
Nyckelord
- Aged
- Antibiotics
- Antineoplastic/adverse effects/*therapeutic use
- Carcinoma
- Hepatocellular/*drug therapy/mortality/*surgery
- Chemotherapy
- Adjuvant
- Disease-Free Survival
- Doxorubicin/adverse effects/*therapeutic use
- Female
- Humans
- Liver Neoplasms/*drug therapy/mortality/*surgery
- *Liver Transplantation
- Male
- Middle Aged
- Prospective Studies
- Recurrence
- Risk Factors
- Survival Rate
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas